

# ATAZANAVIR (MYLAN-ATAZANAVIR; REYATAZ; TEVA-ATAZANAVIR)

- **Drug Class:** Antiretroviral, Protease Inhibitor (Anti-HIV Agent)
- **Enzyme responsible for Drug Metabolism:** UGT1A1
  - Patients with deficient UGT1A1 activity and/or are at higher risk of developing jaundice should consider an alternative to atazanavir for Anti-HIV therapy.
  - Product labeling recommends general monitoring for hyperbilirubinemia. Hyperbilirubinemia may lead to jaundice during therapy especially in those at higher risk. CPIC dosing guidelines state that patients with two decreased function UGT1A1 alleles have a substantial likelihood of developing jaundice. Several studies have reported that impaired UGT1A1 activity is associated with an increased rate of atazanavir discontinuation.
    - Examples of deficient UGT1A1 activity genotypes: UGT1A1\*28/\*28, UGT1A1\*28/\*37, UGT1A1\*37/\*37, UGT1A1\*80/\*80, UGT1A1\*6/\*6
- **Sources:**
  - [http://online.lexi.com.onu.ohionet.org/lco/action/doc/retrieve/docid/patch\\_f/6392?cesid=4rsLqjwT5mE&searchUrl=%2Fico%2Faction%2Fsearch%3Fq%3Datazanavir%26t%3Dname%26va%3Datazanavir#geneconsdrlist](http://online.lexi.com.onu.ohionet.org/lco/action/doc/retrieve/docid/patch_f/6392?cesid=4rsLqjwT5mE&searchUrl=%2Fico%2Faction%2Fsearch%3Fq%3Datazanavir%26t%3Dname%26va%3Datazanavir#geneconsdrlist)
  - <http://online.lexi.com.onu.ohionet.org/lco/action/doc/retrieve/docid/42/6300681>
  - <https://www.pharmgkb.org/guidelineAnnotation/PA166128738>